Eli Lilly And Co (NYSE:MRK) revealed new long-term results on Wednesday, showing promise for treatment in patients with moderate-to-severe atopic dermatitis.
What Happened: The company's data for the ADjoin long-term extension study of Ebglyss (EHB-glihs) will be presented at the European Academy of Dermatology and Venereology Congress (EADV).
The EADV is a leading professional society focused on the fields of dermatology and venereology.
Over 80% of adults and adolescents with moderate-to-severe atopic dermatitis responded to Ebglyss treatment at Week 16 in the ADvocate 1 and 2 monotherapy trials. They continued treatment for up to three years and experienced sustained skin clearance with monthly maintenance dosing.
Also Read: Eli Lilly's Early Alzheimer's Treatment Donanemab Scores Japanese Approval, Its Second Largest Market.
Why It Matters: The FDA approved Ebglyss earlier this month for adults and children 12 years of age and older.
- 84% of the patients taking Ebglyss once monthly and 83% taking Ebglyss every two weeks maintained clear or almost-clear skin (IGA 0,1) at three years.
- 87% of the patients taking Ebglyss once monthly and 79% taking Ebglyss every two weeks achieved or maintained at least 90% improvement in disease extent and severity (EASI-90) at three years.
- 83% of the patients taking Ebglyss once monthly and 91% taking Ebglyss every two weeks did not require high-potency topical corticosteroids or systemic treatments.
Those who participated in the study have moderate-to-severe atopic dermatitis (eczema).
The European Union approved Ebglyss in 2023. Japan approved it in January; additional markets are expected to follow suit.
Lilly has exclusive rights for the development and commercialization of Ebglyss in the U.S. and elsewhere outside Europe.
In Europe, Lilly's partner, Almirall, has licensed the rights to develop and commercialize Ebglyss for dermatology indications, including eczema.
Price Action: Eli Lilly stock is up 0.17% at $926 during the premarket session at last check Wednesday.
- Merck's Experimental Favezelimab/Keytruda Combo Fails In Late-Stage Colorectal Cancer Study
Image: Shutterstock